Search

"Effects of mTOR inhibitor–related proteinuria on progression of cardiac allograft vasculopathy and outcomes among heart transplant recipients"

Recorded live on Tuesday, September 8, 2020, from 2:00 PM ET to 3:00 PM ET • Hosted jointly by the TCC & TxPharm Communities of Practice

"Effects of mTOR inhibitor–related proteinuria on progression of cardiac allograft vasculopathy and outcomes among heart transplant recipients."
(Am J Transplant. 2020 Jun 18. doi: 10.1111/ajt.16155. Online ahead of print.)

In this article:
[The authors] previously described the use of sirolimus (SRL) as primary immunosuppression following heart transplantation (HT). The advantages of this approach include attenuation of cardiac allograft vasculopathy (CAV), improvement in glomerular filtration rate (GFR), and reduced malignancy. However, in some patients SRL may cause significant proteinuria. [The authors] sought to investigate the prognostic value of proteinuria after conversion to SRL. CAV progression and adverse clinical events were studied... [Results] indicate that proteinuria is a marker of baseline renal dysfunction, and that HT recipients who develop proteinuria after conversion to SRL have less attenuation of CAV progression and higher mortality risk.

Speakers:
Richard Daly, MD • Mayo Clinic College of Medicine, Rochester, MN
Sudhir Kushwaha, MD • Mayo Clinic College of Medicine, Rochester, MN

Moderator:
Douglas Jennings, PharmD, FACC, FAHA, FHFSA • Columbia University, New York, NY

Watch Video

AST/AJT Journal Club

See all Journal Clubs

Donate

Donate

Donate

to the American Society of Transplantation

Career Center

Career Center

Career Center

Connecting Transplantation Talent with Opportunities

Patient Education

Patient Education

Educating the Community

The AST initiative, Power2Save, has great resources for patients and patient families.

Educational Content Disclaimer: The content, information, opinions, and viewpoints contained in educational materials housed on and linked from the AST web site are those of the authors or contributors of such materials. While the AST and its committees take great care to screen the credentials of the contributors and make every attempt to review the contents, AST MAKES NO WARRANTY, EXPRESSED OR IMPLIED, as to the completeness or accuracy of the content contained in the educational materials or on this website. The reader of these materials uses these materials at his or her own risk, and AST shall not be responsible for any errors, omissions, or inaccuracies in these materials, whether arising through negligence, oversight, or otherwise. Reliance on any information appearing on this site is strictly at your own risk. Read the full disclaimer.